Evaluating Reduced Blood Monitoring Frequency and the Detection of Hematological Abnormalities in Clozapine-Treated Patients With Schizophrenia: A Chart Review Study From the COVID-19 Pandemic.
Helen ThaiNicholas PreobrazenskiTiChen HsiehCarrie RobertsonOlabisi OwoeyePublished in: Schizophrenia bulletin (2024)
Reducing blood monitoring frequency in patients on clozapine for more than 12 months did not compromise detection of hematological abnormalities.